Fiona J. Collinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fiona J. Collinson has a total of 128 co-authors. Here are the top co-authors by number of shared publications:
- Adel Samson
Leeds Institute of Medical Research at St. James’s, University of Leeds, Leeds LS9 7TF, UK
20 shared publications - Chris Twelves
University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, UK
20 shared publications - Emma J. West
Leeds Institute of Medical Research at St. James’s, University of Leeds, Leeds, United Kingdom
20 shared publications - Kaidre Bendjama
NEC Bio B.V., Netherlands
20 shared publications - Karen J. Scott
Leeds Institute of Medical Research at St. James’s, University of Leeds, Leeds LS9 7TF, UK
20 shared publications - Alan Anthoney
Leeds Institute of Medical Research at St. James’s, University of Leeds, Leeds, United Kingdom
19 shared publications
Latest Publications
- Open Access
- 27 October 2025
- Published by SAGE Publications in Clinical Trials
- Vol. 23 (1) , 113-120
Electronic patient-reported adverse event monitoring in academic early-phase clinical trials: A feasibility study
Background: Adverse event monitoring is essential to monitor safety for oncology patients on early-phase clinical trials. Previous research considers that electronic patient-reported adverse events reporting is feasible and complementary to traditional clinician-led recording. An electronic patient-reported adverse event system was developed to explore the feasibility of this in early trials patients. Methods: A prospective single-arm feasibility study was undertaken at two recruiting hospitals. Participants were adult oncology patients who had recently (<1 month) started receiving a novel anticancer treatment on an academic early-phase trial and had access to the Internet. For a 12-week period, weekly reminders were sent to participants to complete an electronic patient-reported adverse event questionnaire remotely covering symptoms identified as relevant to the recruiting trials. The primary outcome was compliance (proportion of completed questionnaires/expected completions). Secondary outcomes included recruitment rates, attrition, electronic patient-reported outcome versus clinician-recorded adverse events, number of notifications, issues recorded, and patient acceptability. Results: Twenty-three participants consented (76.7% consent rate), 18 remained on study at 12 weeks (4 were withdrawn due to toxicity and 1 patient choice). Compliance with weekly electronic patient-reported adverse event was high, with a cumulative of 85.1% across the 12 weeks. Comparison with clinician-recorded adverse events showed electronic patient-reported adverse event resulted in wider coverage of adverse events: three times as many symptoms reported on electronic patient-reported adverse event (n = 174 last assessment) than recorded in the medical charts (n = 50 last record). End-of-study feedback indicated most patients reflected positively on their time on the study. Conclusions: Remote electronic patient-reported adverse event reporting by patients in early-phase trials is feasible and acceptable. The study highlights some logistical challenges that require consideration in future electronic patient-reported outcome work to ensure adverse events are fully captured and recorded. Trial registration: ClinicalTrials.gov ID: NCT03461939 (first registered: 05/03/2018)
- 27 October 2025
- Published by SAGE Publications in Clinical Trials
- Vol. 23 (1) , 113-120
Open AccessElectronic patient-reported adverse event monitoring in academic early-phase clinical trials: A feasibility study
Background: Adverse event monitoring is essential to monitor safety for oncology patients on early-phase clinical trials. Previous research considers that electronic patient-reported adverse events reporting is feasible and complementary to traditional clinician-led recording. An electronic patient-reported adverse event system was developed to explore the feasibility of this in early trials patients. Methods: A prospective single-arm feasibility study was undertaken at two recruiting hospitals. Participants were adult oncology patients who had recently (<1 month) started receiving a novel anticancer treatment on an academic early-phase trial and had access to the Internet. For a 12-week period, weekly reminders were sent to participants to complete an electronic patient-reported adverse event questionnaire remotely covering symptoms identified as relevant to the recruiting trials. The primary outcome was compliance (proportion of completed questionnaires/expected completions). Secondary outcomes included recruitment rates, attrition, electronic patient-reported outcome versus clinician-recorded adverse events, number of notifications, issues recorded, and patient acceptability. Results: Twenty-three participants consented (76.7% consent rate), 18 remained on study at 12 weeks (4 were withdrawn due to toxicity and 1 patient choice). Compliance with weekly electronic patient-reported adverse event was high, with a cumulative of 85.1% across the 12 weeks. Comparison with clinician-recorded adverse events showed electronic patient-reported adverse event resulted in wider coverage of adverse events: three times as many symptoms reported on electronic patient-reported adverse event (n = 174 last assessment) than recorded in the medical charts (n = 50 last record). End-of-study feedback indicated most patients reflected positively on their time on the study. Conclusions: Remote electronic patient-reported adverse event reporting by patients in early-phase trials is feasible and acceptable. The study highlights some logistical challenges that require consideration in future electronic patient-reported outcome work to ensure adverse events are fully captured and recorded. Trial registration: ClinicalTrials.gov ID: NCT03461939 (first registered: 05/03/2018)
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Patient demographics and disease summary
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Patient demographics and disease summary
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Detection of TG6002, nAb, 5-FC, 5-FU, and F-BAL in plasma following treatment. A, Plasma samples analyzed by qPCR to detect TG6002 following treatment. Values stated are the number of copies per milliliter (c/mL). B, Serum nAb titers (IC50) for n = 15 patients, sample availability–dependent. * P < 0.05, paired t test. C, Serum 5-FC, 5-FU, and F-BAL concentrations at day 8 following treatment (n = 13 patients), sample availability–dependent. Cohort 1: purple, cohort 2: green, cohort 3: blue, and cohort 4: red. BLD, below limit of detection; BLQ, below the limit of quantification; C, cycle; D, day; nAb, neutralizing antibody; ND, not done due to insufficient sample.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Detection of TG6002, nAb, 5-FC, 5-FU, and F-BAL in plasma following treatment. A, Plasma samples analyzed by qPCR to detect TG6002 following treatment. Values stated are the number of copies per milliliter (c/mL). B, Serum nAb titers (IC50) for n = 15 patients, sample availability–dependent. * P < 0.05, paired t test. C, Serum 5-FC, 5-FU, and F-BAL concentrations at day 8 following treatment (n = 13 patients), sample availability–dependent. Cohort 1: purple, cohort 2: green, cohort 3: blue, and cohort 4: red. BLD, below limit of detection; BLQ, below the limit of quantification; C, cycle; D, day; nAb, neutralizing antibody; ND, not done due to insufficient sample.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
AEs summarized by relationship to TG6002 and 5-FC.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
AEs summarized by relationship to TG6002 and 5-FC.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Detection of TG6002 in patient tumor biopsies. A, Table summary of data collated from assays to detect the presence of TG6002 in tumor biopsies: qPCR and qRT-PCR to detect viral nucleic acids, plaque assay to detect replication-competent virus (infectious virus particles per biopsy), IHC to determine the presence of virus protein, and 5-FU (pg/mg) to demonstrate transgene activity. Samples are designated as either positive or negative/below the limit of detection for each assay. B, Representative examples of positively stained tumor cells by IHC for patients 04 (day 4) and 06 (day 8) (left; brown DAB) and negative control (right; secondary antibody alone). Scale bars, 200 μm. BLQ, below the limit of quantification; D4, day 4; D8, day 8; ND, not done due to insufficient sample; NP, not planned.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Detection of TG6002 in patient tumor biopsies. A, Table summary of data collated from assays to detect the presence of TG6002 in tumor biopsies: qPCR and qRT-PCR to detect viral nucleic acids, plaque assay to detect replication-competent virus (infectious virus particles per biopsy), IHC to determine the presence of virus protein, and 5-FU (pg/mg) to demonstrate transgene activity. Samples are designated as either positive or negative/below the limit of detection for each assay. B, Representative examples of positively stained tumor cells by IHC for patients 04 (day 4) and 06 (day 8) (left; brown DAB) and negative control (right; secondary antibody alone). Scale bars, 200 μm. BLQ, below the limit of quantification; D4, day 4; D8, day 8; ND, not done due to insufficient sample; NP, not planned.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Trial schema and sampling schedule. A, Trial schema depicting treatment schedule of two planned cycles of IHA TG6002 and oral 5-FC. B, Patient blood and tissue samples taken at various time points prior to and during treatment. Blood samples were specific for downstream analyses: translational (red), pharmacokinetic (blue), pharmacodynamic (green), neutralizing antibody (purple), and tissue biopsies (black). SC, screening; BS, baseline; C, cycle; D, day. (Created with BioRender.com.)
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Trial schema and sampling schedule. A, Trial schema depicting treatment schedule of two planned cycles of IHA TG6002 and oral 5-FC. B, Patient blood and tissue samples taken at various time points prior to and during treatment. Blood samples were specific for downstream analyses: translational (red), pharmacokinetic (blue), pharmacodynamic (green), neutralizing antibody (purple), and tissue biopsies (black). SC, screening; BS, baseline; C, cycle; D, day. (Created with BioRender.com.)
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
MRNA sequencing of patient PBMCs revealing clustering of DEGs involved in immune activation and response pathways to treatment. A, The number of upregulated ssDEGs in the post-treatment samples relative to pretreatment controls for days 2 and 15 post-infusion. B, Volcano plots for three patients that highlight nine commonly expressed ssDEGs (red: downregulated DEGs, blue: upregulated DEGs, black: nonsignificant changes to DEGs, and green: specific highlighted ssDEGs). C, Cluster plot of the nine commonly expressed ssDEGs in three patients which correspond to (D) immune-related GO pathways. E, GO analysis showing cluster plots of all upregulated ssDEGs in three patients at days 2 and 15. DEGs are defined as up-/downregulated from baseline, Padj < 0.05; ssDEGs are defined as ± >2 log2 fold change and Padj < 0.05.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
MRNA sequencing of patient PBMCs revealing clustering of DEGs involved in immune activation and response pathways to treatment. A, The number of upregulated ssDEGs in the post-treatment samples relative to pretreatment controls for days 2 and 15 post-infusion. B, Volcano plots for three patients that highlight nine commonly expressed ssDEGs (red: downregulated DEGs, blue: upregulated DEGs, black: nonsignificant changes to DEGs, and green: specific highlighted ssDEGs). C, Cluster plot of the nine commonly expressed ssDEGs in three patients which correspond to (D) immune-related GO pathways. E, GO analysis showing cluster plots of all upregulated ssDEGs in three patients at days 2 and 15. DEGs are defined as up-/downregulated from baseline, Padj < 0.05; ssDEGs are defined as ± >2 log2 fold change and Padj < 0.05.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Adaptive T-cell responses to treatment. T-cell function was assessed by ELISpot assay, which showed an IFNγ-release response to CEA and TG6002. A, Data expressed as the mean fold change ± SEM SFU of post-treatment samples compared with baseline. n = 6 patients, sample availability–dependent. B, Representative examples of SFU from two patients showing BS and post-treatment samples, in triplicate, depicting responses to CEA and TG6002. C and D, TCRβ sequencing examined the T-cell clonal response to TG6002 infusion. CDR3 sequences were matched to known TCRs using the McPAS database. TCRs matched to cancer antigen epitopes (C) and neoantigen epitopes (D) are shown; data are expressed as number of total matched TCRs (x-axis) vs. the sum of productive frequencies of matched TCRs (y-axis). Cohort 1; purple, cohort 2: green, and cohort 3: blue. SFU, spot-forming units; CDR3, complementary-determining region 3; BS, baseline.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Adaptive T-cell responses to treatment. T-cell function was assessed by ELISpot assay, which showed an IFNγ-release response to CEA and TG6002. A, Data expressed as the mean fold change ± SEM SFU of post-treatment samples compared with baseline. n = 6 patients, sample availability–dependent. B, Representative examples of SFU from two patients showing BS and post-treatment samples, in triplicate, depicting responses to CEA and TG6002. C and D, TCRβ sequencing examined the T-cell clonal response to TG6002 infusion. CDR3 sequences were matched to known TCRs using the McPAS database. TCRs matched to cancer antigen epitopes (C) and neoantigen epitopes (D) are shown; data are expressed as number of total matched TCRs (x-axis) vs. the sum of productive frequencies of matched TCRs (y-axis). Cohort 1; purple, cohort 2: green, and cohort 3: blue. SFU, spot-forming units; CDR3, complementary-determining region 3; BS, baseline.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
AEs summarized by relationship to grade.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
AEs summarized by relationship to grade.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Treatment cohorts with patient trial/manuscript ID designation
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
Treatment cohorts with patient trial/manuscript ID designation